Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospidelong in Disseminated Gastric Cancer
NCT06232434Phase 3Recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prospidelong in gastric cancer (GC) (2 arms). Primary endpoint: Overall Survival at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
Prospidelong
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06232434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232434.